213 related articles for article (PubMed ID: 28864631)
1. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
J Nucl Med; 2018 Jan; 59(1):93-99. PubMed ID: 28864631
[TBL] [Abstract][Full Text] [Related]
2. Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6.
Garousi J; Lindbo S; Honarvar H; Velletta J; Mitran B; Altai M; Orlova A; Tolmachev V; Hober S
Bioconjug Chem; 2016 Nov; 27(11):2678-2688. PubMed ID: 27740752
[TBL] [Abstract][Full Text] [Related]
3. Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with
Lindbo S; Garousi J; Mitran B; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Tolmachev V
Mol Pharm; 2018 Jul; 15(7):2674-2683. PubMed ID: 29865791
[TBL] [Abstract][Full Text] [Related]
4. Selection of the optimal macrocyclic chelators for labeling with
von Witting E; Garousi J; Lindbo S; Vorobyeva A; Altai M; Oroujeni M; Mitran B; Orlova A; Hober S; Tolmachev V
Eur J Pharm Biopharm; 2019 Jul; 140():109-120. PubMed ID: 31082509
[TBL] [Abstract][Full Text] [Related]
5. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours.
Garousi J; Lindbo S; Borin J; von Witting E; Vorobyeva A; Oroujeni M; Mitran B; Orlova A; Buijs J; Tolmachev V; Hober S
Eur J Pharm Biopharm; 2019 Jan; 134():37-48. PubMed ID: 30408518
[TBL] [Abstract][Full Text] [Related]
7. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
[TBL] [Abstract][Full Text] [Related]
8. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
9. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the first
Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
[TBL] [Abstract][Full Text] [Related]
11. Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle.
Garousi J; von Witting E; Borin J; Vorobyeva A; Altai M; Vorontsova O; Konijnenberg MW; Oroujeni M; Orlova A; Tolmachev V; Hober S
Biomaterials; 2021 Jan; 266():120381. PubMed ID: 33120197
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of
Bragina O; von Witting E; Garousi J; Zelchan R; Sandström M; Orlova A; Medvedeva A; Doroshenko A; Vorobyeva A; Lindbo S; Borin J; Tarabanovskaya N; Sörensen J; Hober S; Chernov V; Tolmachev V
J Nucl Med; 2021 Apr; 62(4):493-499. PubMed ID: 32817142
[TBL] [Abstract][Full Text] [Related]
13. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m.
Garousi J; Lindbo S; Mitran B; Buijs J; Vorobyeva A; Orlova A; Tolmachev V; Hober S
Sci Rep; 2017 Nov; 7(1):14780. PubMed ID: 29116215
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
[TBL] [Abstract][Full Text] [Related]
16. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.
Deyev SM; Vorobyeva A; Schulga A; Abouzayed A; Günther T; Garousi J; Konovalova E; Ding H; Gräslund T; Orlova A; Tolmachev V
Int J Biol Macromol; 2020 Feb; 145():216-225. PubMed ID: 31863835
[TBL] [Abstract][Full Text] [Related]
17. Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules.
Rinne SS; Xu T; Dahlsson Leitao C; Ståhl S; Löfblom J; Orlova A; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075258
[TBL] [Abstract][Full Text] [Related]
18. ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers.
Garousi J; Lindbo S; Nilvebrant J; Åstrand M; Buijs J; Sandström M; Honarvar H; Orlova A; Tolmachev V; Hober S
Cancer Res; 2015 Oct; 75(20):4364-71. PubMed ID: 26297736
[TBL] [Abstract][Full Text] [Related]
19. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
Qi S; Hoppmann S; Xu Y; Cheng Z
Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
[TBL] [Abstract][Full Text] [Related]
20. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
